FDA perspective on companion diagnostics: an evolving paradigm

Area of Science:

• Oncology
• Regulatory Science
• Molecular Diagnostics

Background:

• Targeted cancer therapies require precise molecular lesion identification.
• Diagnostic tests are crucial for selecting patients for targeted treatments.
• The co-development model integrates diagnostic and therapeutic product development.

Purpose of the Study:

• To explain the regulatory framework for co-developing diagnostics and therapeutics.
• To highlight the FDA's policy on co-approval of essential diagnostics.
• To discuss the challenges and promise of companion diagnostic co-development.

Main Methods:

• Review of FDA policy on co-development.
• Analysis of the regulatory pathway for paired diagnostic and therapeutic products.
• Examination of the role of clinical trials in regulatory decision-making.

Main Results:

• Co-development ensures safety and effectiveness of targeted therapies.
• FDA mandates co-approval when diagnostics are essential for therapy use.
• Regulatory processes are in place to manage co-development without delays.

Conclusions:

• The co-development model is increasingly used for targeted cancer drugs.
• Advancements in diagnostics and targeted therapies will evolve regulatory approaches.
• Simplified regulatory pathways may emerge, balancing new challenges with patient benefit.